Trial Profile
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures:a Double-blind, Randomized, Active-controlled, Parallel-group, Multicenter Clinical Study.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Eslicarbazepine acetate (Primary) ; Carbamazepine
- Indications Partial epilepsies
- Focus Registrational; Therapeutic Use
- Sponsors BIAL - Portela C S.A.
- 06 Dec 2022 Results of post hoc analysis(n=288) assessing efficacy and safety/tolerability of eslicarbazepine acetate (ESL) monotherapy vs. controlled-release carbamazepine (CBZ-CR) in PTE vs. non-PTE patients presented at the 76th Annual Meeting of the American Epilepsy Society
- 22 Apr 2021 Results assessing 10 years of post-marketing surveillance (PMS) safety data of eslicarbazepine acetate collected from randomised clinical trials in adults: BIA-2093-201, -301, -302 -303, -304 and -311, presented at the 73rd Annual Meeting of the American Academy of Neurology.
- 22 Apr 2021 Results of post hoc analysis from NCT02484001 and NCT01162460; evaluating the lipid changes in adult patients with newly diagnosed focal-onset seizures, presented at the 73rd Annual Meeting of the American Academy of Neurology